Show document

A+ | A- | | SLO | ENG

Title: Sistemsko zdravljenje z interferoni v onkologiji Authors: ID Reberšek, Martina (Author) Files: PDF - Presentation file, download (157,81 KB)   Language: Slovenian Typology: 1.04 - Professional Article Organization: OI - Institute of Oncology Abstract: Interferoni so pomembni za komunikacijo med celicami, ki so vključene v obrambo našega imunskega sistema. V onkologiji jih predpisujemo pri zdravljenju različnih rakov, v predpisanih odmerkih. Najpomembnejšo vlogo imajo v adjuvantnem zdravljenju malignega melanoma pri velikih odmerkih z interferonom--α2b tipa. Maligni melanom je v več kot 80 odstotkih ozdravljiva bolezen, če se kirurško odstranjuje v zgodnjih fazah. V primeru pozitivnih regionalnih bezgavk se v več kot polovici teh bolnikov razvije metastatska bolezen, ki je neozdravljiva. Pri bolnikih z večjo verjetnostjo ponovitve bolezni v stadijih IIB, IIC in III se tako priporoča adjuvantna terapija z visokim odmerkom interferona-α2b v Evropi, v stadiju IIIA z visokim tveganjem (velikost metastaze v regionalni bezgavki > 1 mm) in v stadijih IIIB in IIIC pa v ZDA priporočajo zdravljenje z visokim odmerkom anti-CTLA monoklonalnega protitelesa ipilimumaba. Neželeniučinki visokega odmerka interferona so obvladljivi z dobro edukacijo in s sodelovanjem bolnikov. Keywords: interferoni, sistemsko zdravljenje, onkologija Publication status: Published Publication version: Version of Record Year of publishing: 2017 Number of pages: str. 12-14 Numbering: Letn. 21, št. 2 COBISS.SI-ID: 2869115  UDC: 616-006 ISSN on article: 1408-1741 Publication date in DiRROS: 16.03.2018 Views: 386 Downloads: 14 Metadata:    Cite this work Plain text BibTeX EndNote XML EndNote/Refer RIS ABNT ACM Ref AMA APA Chicago 17th Author-Date Harvard IEEE ISO 690 MLA Vancouver : Copy citation

Share: Hover the mouse pointer over a document title to show the abstract or click on the title to get all document metadata.

Record is a part of a journal

Title:	Onkologija. strokovni časopis za zdravnike
Shortened title:	Onkologija
Publisher:	Onkološki inštitut
ISSN:	1408-1741
COBISS.SI-ID:	65324032

Secondary language

Language:	English
Title:	Systemic treatment with interferones in oncology
Abstract:	Interferons are an integral part of communication between the cells responsible for triggering the protective defenses of our immune system. In oncology, they are administered in prescribed doses to treat different cancers. They are of utmost importance in adjuvant treatment of malignant melanoma, namely in high doses of interferon α2b. Malignant melanoma is a highly aggressive malignant disease that is curable in more than 80 % of patients, if surgically removed in early stages of the disease. If, upon detection, regional lymph nodes are already positive, an incurable metastatic disease develops in more than 50 % of patients. For patients with a greater possibility of disease recurrence (stages IIB, IIC, and III), adjuvant therapy with a high dose of interferon α2b is recommended in Europe; while for high-risk stage IIIA (node metastasis > 1 mm) and stages IIIB and IIIC, a high dose of the anti-CTLA monoclonal antibody ipilimumab is recommended in the United States. The side effects of a high dose of interferon are manageable with a well-educated and compliant patient.

Collection

This document is a part of these collections:

1. Onkologija : strokovni časopis za zdravnike

Back